Loading…
Loading…
The moves that matter — curated from across forex, stocks and crypto, and readable in full right here.
Updated 25 Jun, 09:14 pm

RBC Capital has significantly increased its price target for Verastem to $15.00 , reflecting strong confidence in the biopharmaceutical company's outlook. The biopharmaceutical company reported encouraging preliminary data from its TARGET-D 101 Phase 1/2 clinical trial for VS-737

Morgan Stanley reiterated an "Overweight" rating for Vistra Corp. (NYSE: VST) , signaling a positive investment outlook despite a minor adjustment to its price target . Vistra Corp. is actively boosting shareholder value through a substantial share repurchase program , supported
Headlines provided by Investing.com